Portal Biotechnologies

Executive Summary

Portal Biotechnologies, a San Francisco-based biotech founded in 2019, is developing a proprietary membrane-based delivery system that uses mechanical disruption to introduce diverse cargo into cells without transfection reagents. This platform aims to democratize cell therapies and enable novel drug discovery insights by providing a universal cell engineering tool. The company's technology addresses key limitations of current delivery methods, such as viral vectors and electroporation, by offering a non-viral, reagent-free approach that can deliver a wide range of molecules including proteins, nucleic acids, and gene-editing complexes. With applications in cell therapy, gene therapy, and drug discovery, Portal's platform has the potential to significantly accelerate the development of next-generation therapeutics. Despite being in an early stage, the company's innovative approach positions it as a promising player in the cell engineering and drug delivery space.

Upcoming Catalysts (preview)

• Q4 2026Formation of strategic partnership with a major pharmaceutical company for cell therapy applications40% success
• Q3 2026Series A funding round to advance platform development and expand team60% success
• Q1 2027Release of proof-of-concept data demonstrating in vivo delivery of gene-editing cargo50% success